The Independent Medical Alliance doctor weighs in on what is still unknown about the long-term safety of GLP-1 drugs used by millions of Americans.
Recap by typeshit. Post by Facebook on Facebook.
A shared explainer on how eating habits and food choices matter once you begin a GLP-1 medication. General guidance, no new findings.
Williams explains how retatrutide's glucagon pathway works and cautions that knockoff Reta sold online is a real risk. FDA approval could come in late 2027 or 2028.
A brief post argues buyers need accurate information on peptides because a lot of the popular messaging is misleading.
Men's Journal reports the coroner's findings on the cause of Norton's death, with the dose detail coming from the coroner rather than earlier speculation.
The telehealth company says it serves nearly 3 million people and is sticking with 2030 targets of at least $6.5 billion in revenue.
AllSci looks at how Eli Lilly's third quarter shaped up, with retatrutide adding weight to its GLP-1 lineup and more cancer drugs moving through development.
Loading…